ST. LOUIS, May 9, 2014 /PRNewswire-USNewswire/ -- Today, K-V Pharmaceutical Company ("KV") announced that Paul Williams – a seasoned executive with extensive experience in both neonatal health and the bio-pharmaceuticals business – has joined the company to lead its Women's Healthcare Division.
KV recently underwent a broader reorganization of the Company's operations, creating two new business units: the Women's Healthcare Division, led by Williams, and the Maternal Health Division, led by healthcare veteran Gregg Raybuck, who joined the KV executive team last year.
"Paul's entrepreneurial spirit and extensive leadership background will be a valuable asset in helping us shape and grow the newly formed Women's Healthcare Division," said Greg Divis, KV CEO. "KV is undergoing a number of changes and we're excited to have someone of Paul's caliber joining us at this pivotal time."
Williams joins KV from Actavis, Inc. where we he was Senior Vice President and General Manager of Intellogics. While at Actavis, he built and led a start-up division to deliver an innovative solution for biologics specialty distribution. Prior to joining Actavis, Williams led a number of high-profile assignments at MedImmune, Inc., as Vice President of Sales and Marketing Operations, Vice President of Sales, and ultimately as Vice President and Head of the $1 billion global Pediatric Infectious Disease franchise.
"I'm excited to be part of the KV team and look forward to impacting its mission to advance women's healthcare and contributing to the company's next phase of growth," said Williams.
About KV Pharmaceutical
K-V Pharmaceutical Company is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. The Company is committed to advancing the health of women across the stages of their lives. For further information about K-V Pharmaceutical Company, please visit www.kvph.com.
Cautionary Note Regarding Forward-Looking Statements
This release contains various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 (the "PSLRA") and which may be based on or include assumptions concerning our future operations, future results and prospects. Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could," "potential" and other expressions that indicate future events and trends, although not all forward-looking statements contain these words.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the PSLRA's "safe harbor" provisions, we provide the following cautionary statements with regard to KV, identifying important economic, competitive, political, regulatory and technological factors, among others, that could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions. Such factors include (but are not limited to):
- KV's ability to execute its business plan;
- KV's ability to achieve revenue from the sale of Makena® consistent with its business expectations, including as a result of competition from approved and unapproved products;
- unfavorable resolutions of private and governmental litigation and governmental inquiries and other risks and costs associated with litigation;
- disruptions in the supply of raw materials or finished product;
- risks, costs and delays associated with clinical trials;
- issues associated with KV's intellectual property rights, licenses and exclusivity;
- extensive industry regulation;
- KV's ability to meet its obligations under the Credit and Guaranty Agreement dated September 16, 2013 or other indebtedness; and
- the ability of KV and its affiliates to maintain contracts that are critical to their operation, including the ability to obtain and maintain normal terms with their vendors, customers and service providers and to retain key executives, managers and employees.
This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements.
Because the factors referred to above as well as additional factors and assumptions not identified above could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. All forward-looking statements attributable to us are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements. " Further, any forward-looking statement speaks only as of the date on which it is made and we are under no obligation to update any of the forward-looking statements after the date of this release. New factors emerge from time to time, and it is not possible for us to predict which factors will arise, when they will arise and/or their effects. In addition, we cannot assess the impact of each factor on our future business or financial condition or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.
SOURCE K-V Pharmaceutical Company